DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021
May 05 2021 - 5:00PM
Montrouge, France, May 5, 2021
DBV Technologies Announces Filing
of its First
Form 10-Q for the First Quarter
of 2021
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced the filing of its first
Form 10-Q for the quarter ended March 31, 2021 with the U.S.
Securities and Exchange Commission (SEC).
This document can be accessed on the Investors
& Media section of the Company's website at
www.dbv-technologies.com. In addition, this Form 10-Q is available
on the SEC’s website at www.sec.gov.
About DBV Technologies DBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, DBV’s method of delivering biologically active compounds to
the immune system through intact skin. With this new class of
non-invasive product candidates, the Company is dedicated to safely
transforming the care of food allergic patients. DBV’s food
allergies programs include ongoing clinical trials of Viaskin
Peanut. DBV Technologies has global headquarters in Montrouge,
France, and North American operations in Summit, NJ. The Company’s
ordinary shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345), part of the SBF120 index, and the
Company’s ADSs (each representing one-half of one ordinary share)
are traded on the Nasdaq Global Select Market (Ticker: DBVT).
DBV Investor Relations Contact
Anne Pollak+ 1 (857) 529-2363anne.pollak@dbv-technologies.com
DBV Media Contact Angela
Marcucci+1 (646) 842-2393angela.marcucci@dbv-technologies.com
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Mar 2024 to Apr 2024
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Apr 2023 to Apr 2024